financetom
Business
financetom
/
Business
/
Arbor Realty Trust Q4 Distributable Earnings, Net Interest Income Decrease
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arbor Realty Trust Q4 Distributable Earnings, Net Interest Income Decrease
Feb 21, 2025 6:11 AM

08:53 AM EST, 02/21/2025 (MT Newswires) -- Arbor Realty Trust ( ABR ) reported Q4 distributable earnings Friday of $0.40 per diluted share, down from $0.51 a year earlier.

Four analysts polled by FactSet expected $0.38.

Net interest income for the quarter ended Dec. 31 was $82.9 million, down from $103.6 million a year earlier.

Comparable analyst estimates were not readily available.

The company said it will distribute an unchanged quarterly dividend of $0.43 per share, payable March 21 to shareholders of record on March 7.

Shares of the company were 0.2% higher in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Copyright 2023-2026 - www.financetom.com All Rights Reserved